Clinical Trial Update: Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated ibritumomab tiuxetan for non-follicular CD20+ indolent lymphomas; the study was terminated and results were posted in May 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2013-05-31